Peeling Back The Layers: Exploring RxSight Through Analyst Insights
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
Needham analyst David Saxon maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 34.7% and a total
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Morgan Stanley analyst Patrick Wood maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 61.9% and a
Companies Like RxSight (NASDAQ:RXST) Can Afford To Invest In Growth